Posts

BMS pushes key Cobenfy and milvexian readouts to 2027 amid strong quarter and raised guidance

on

BMS CEO Boerner Says No Compulsion to Chase Deals Despite Quiet M&A Year

on

BMS expands AI footprint with Nvidia, aiming for most powerful AI factory in life sciences

on

Bristol lays out KRAS med Krazati's stumble in confirmatory colorectal cancer trial

on

Bristol Myers details Krazati confirmatory study failure in colorectal cancer

on

Kardigan’s $320M IPO pitch: Three borrowed heart drugs, one proven cardio CEO

on

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Use AI and Real‑World Data to Improve Clinical Trial Success

on

Cytokinetics Succeeds Against Bristol Myers' Failure in HCM: FDA Approves Myqorzo as Camzyos Fails nHCM Trial

on

Bristol Myers Squibb's Pipeline Focus in Pivotal 2026

on

Bristol Myers Squibb and Bain Capital Launch New Autoimmune Disease Biotech Company

on

FDA Approves Opdivo (Nivolumab) for Classical Hodgkin Lymphoma Indications

on

BMS Receives FDA Approval for Sotyktu in Psoriatic Arthritis Treatment

on

Bristol Myers Squibb Announces Positive Phase 3 Results for Mezigdomide in Multiple Myeloma

on

BMS and Microsoft Partner to Advance AI-Driven Lung Cancer Detection

on

Bristol Myers Squibb Completes $4.8 Billion Acquisition of Mirati Therapeutics

on

FDA Approves Cytokinetics' Myqorzo for Obstructive Hypertrophic Cardiomyopathy, Positioning It Against BMS's Camzyos

on

Harbour BioMed inks $90M upfront, $1B+ antibody alliance with Bristol Myers Squibb

on

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig in Advanced Triple-Negative Breast Cancer

on

Bristol Myers Squibb Delays Cobenfy Alzheimer's Psychosis Trial Readout Due to Site Irregularities

on

Spotlight On: Big Pharma's Big Bets on In Vivo Cell Therapy

on